Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065286 | 1.00 | DPP4 (0.30) | DPP4 | |
| SCHEMBL22554851 | 1.00 | DPP4 (0.30) | DPP4 | |
| SCHEMBL22208153 | 1.00 | DPP4 (0.30) | DPP4 | |
| SCHEMBL2908778 | 0.84 | POLB (0.32) | — | |
| SCHEMBL3372261 | 0.84 | POLB (0.32) | — | |
| SCHEMBL2908775 | 0.84 | POLB (0.32) | — | |
| SCHEMBL23825814 | 0.82 | DPP4 (0.31) | DPP4 | |
| SCHEMBL6120413 | 0.82 | DPP4 (0.31) | DPP4 | |
| SCHEMBL28250719 | 0.82 | GABRR1 (0.38) | DPP4 | |
| SCHEMBL14480018 | 0.79 | DPP4 (0.41) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-11-16 | — | — | US | disclosed |
| US-9498540-B2 | Cell proliferation inhibitors and conjugates thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2968591-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| WO-2014151030-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| EP-2758402-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | Pfizer Inc (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | DPP4 4206/4885 |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | DPP4 4206/4885 |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | DPP4 2838/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | DPP4 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.